Description
Perjeta 420 mg contains Pertuzumab, a recombinant humanized monoclonal antibody designed to target the HER2 (Human Epidermal Growth Factor Receptor 2) protein. It is administered via intravenous infusion and is widely used in modern oncology for HER2-positive breast cancer treatment.
🔬 Mechanism of Action
Pertuzumab binds to a specific region (subdomain II) of the HER2 receptor, preventing it from pairing (dimerizing) with other HER receptors. As a result, it blocks tumor growth signaling pathways.
When used together with trastuzumab, it provides dual HER2 blockade, significantly enhancing anti-tumor activity.
💊 Indications
Perjeta 420 mg is indicated for:
- HER2-positive metastatic breast cancer
- Neoadjuvant treatment of HER2-positive early breast cancer
- Adjuvant treatment of HER2-positive early breast cancer
It is typically administered in combination with trastuzumab and chemotherapy as part of standard treatment regimens.
📌 Key Features of Perjeta 420 mg
- Strength: 420 mg
- Dosage Form: Intravenous infusion
- Therapeutic Class: Anti-HER2 Monoclonal Antibody
- Administration: IV infusion in hospital or oncology clinic
- Monitoring: Cardiac function monitoring (e.g., LVEF assessment) required during therapy
⚕️ Benefits of Pertuzumab
- Provides dual HER2 blockade when combined with trastuzumab
- Improves progression-free and overall survival
- Enhances treatment response in early and metastatic breast cancer
- Key component of standard HER2-targeted therapy
⚠️ Precautions
- Infusion-related reactions may occur
- Risk of cardiotoxicity; cardiac monitoring required
- Not recommended during pregnancy
- Use strictly under oncologist supervision
Perjeta 420 mg (Pertuzumab Injection) is an advanced targeted therapy that plays a crucial role in the treatment of HER2-positive breast cancer, helping improve survival outcomes when used as part of a comprehensive oncology treatment plan.
